Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Argenx SE
  6. Summary
    ARGX   NL0010832176

ARGENX SE

(ARGX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Bruxelles
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
274.9(c) 276.4(c) 272(c) 272.7(c) 280.1(c) Last
50 338 34 573 81 439 56 188 106 218 Volume
-1.47% +0.55% -1.59% +0.26% +2.71% Change
More quotes
Estimated financial data (e)
Sales 2021 443 M 519 M 519 M
Net income 2021 -336 M -394 M -394 M
Net cash position 2021 1 558 M 1 827 M 1 827 M
P/E ratio 2021 -42,4x
Yield 2021 -
Sales 2022 214 M 251 M 251 M
Net income 2022 -731 M -857 M -857 M
Net cash position 2022 1 276 M 1 496 M 1 496 M
P/E ratio 2022 -22,8x
Yield 2022 -
Capitalization 14 397 M 16 900 M 16 880 M
EV / Sales 2021 29,0x
EV / Sales 2022 61,3x
Nbr of Employees 336
Free-Float 99,1%
More Financials
Company
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme... 
More about the company
Ratings of argenx SE
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about ARGENX SE
09/07ARGENX : Morgan Stanley Downgrades argenx SE to Equalweight from Overweight, Adj..
MT
09/03ARGENX : to Present at Upcoming Investor Conferences
AQ
09/02ARGENX : to Present at Upcoming Investor Conferences
PU
08/27European ADRs Rise Nearly 1% Friday Morning
MT
08/25ARGENX : Says EMA Validates Marketing Authorization Application for Rare Autoimm..
MT
08/25ARGENX : Neuromuscular Disease Drug Accepted For European Medicines Agency Revie..
MT
08/25ARGENX : Announces Validation of European Marketing Authorization Application fo..
AQ
08/11PRESS RELEASE : Just - Evotec Biologics opens J.POD 1 US in Redmond, Washington
DJ
08/04ARGENX : argenx to Present at 2021 Wedbush PacGrow Virtual Healthcare Conference
PU
08/04ARGENX : to Present at 2021 Wedbush PacGrow Virtual Healthcare Conference
AQ
08/03DGAP-ADHOC : Evotec SE: Positive Phase IIb data for investigational P2X3 antagon..
DJ
08/02DGAP-ADHOC : Evotec SE Announces Confidential Submission of Draft Registration S..
DJ
07/30European ADRs Drop Nearly 0.5% as Miners, Drillers Lag
MT
07/29ARGENX : Swings to H1 Earnings as Revenue Jumps From Last Year
MT
07/29ARGENX : argenx Reports Half Year 2021 Financial Results and Provides Second Qua..
PU
More news
News in other languages on ARGENX SE
09/03EVOTEC IM FOKUS : Master of the Forschung im Börsenorbit
08/27Les ADR européens progressent de près de 1% vendredi matin
08/25Efgartigimod van Argen-x krijgt Europese validatie
08/11Evotec bestätigt Prognose - Investitionen belasten Ergebnis
08/11DGAP-NEWS : Just - Evotec Biologics eröffnet J.POD 1 US in Redmond, Washington
More news
Analyst Recommendations on ARGENX SE
More recommendations
Chart ARGENX SE
Duration : Period :
argenx SE Technical Analysis Chart | ARGX | NL0010832176 | MarketScreener
Technical analysis trends ARGENX SE
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 280,10 €
Average target price 310,66 €
Spread / Average Target 10,9%
EPS Revisions
Managers and Directors
Tim van Hauwermeiren Chief Executive Officer & Executive Director
Karl Gubitz Chief Financial Officer
Peter K. M. Verhaeghe Chairman
Hans J. W. de Haard Chief Scientific Officer
Wim Parys Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ARGENX SE15.74%16 900
GILEAD SCIENCES, INC.22.91%89 785
BIONTECH SE340.60%86 750
WUXI APPTEC CO., LTD.35.75%69 350
REGENERON PHARMACEUTICALS34.93%67 775
VERTEX PHARMACEUTICALS-20.33%48 850